Purple Biotech (PPBT) Total Current Liabilities (2014 - 2026)

Purple Biotech (PPBT) has reported Total Current Liabilities for 13 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 18.55% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $1.8 million, a 18.55% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, up 94.46% from the prior year.
• Total Current Liabilities was $1.8 million for Q2 2026 at Purple Biotech, down from $4.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $9.7 million in Q4 2023 and troughed at $1.8 million in Q2 2026.
• A 5-year average of $5.6 million and a median of $5.8 million in 2022 frame the typical range for Total Current Liabilities.
• The widest YoY moves for Total Current Liabilities: up 94.46% in 2025, down 67.59% in 2025.
• Over 5 years, Total Current Liabilities stood at $7.1 million in 2022, then soared by 37.45% to $9.7 million in 2023, then plunged by 58.9% to $4.0 million in 2024, then soared by 94.46% to $7.8 million in 2025, then sank by 77.0% to $1.8 million in 2026.
• The last three Total Current Liabilities figures came in at $1.8 million (Q2 2026), $4.6 million (Q1 2026), and $7.8 million (Q4 2025), per Business Quant data.